tDCS and rTMS in Patients With Early Disorders of Consciousness
A Prospective Randomized Controlled Study of the Efficacy of tDCS and rTMS in Promoting Wakefulness in Patients With Early Disorders of Consciousness
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Yan Zhang, MD
- Phone Number: 0086-13671376710
- Email: zhangylq@sina.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age 18-80 years
- diagnosis of stroke or ischemic-hypoxic encephalopathy confirmed by neuroimaging (head MRI)
- DOC, Glasgow coma score (GCS) <12 4.2-4 weeks of DOC
5.informed consent obtained from the patient's legal representative.
Exclusion Criteria:
- foreign bodies such as metal or electronic devices in the skull (inside or on the surface of the tissue at the treatment stimulation site)
- pacemaker or cochlear implants
- history of epilepsy and family history of epilepsy
- large cranial defects
- significant cerebral edema lesions in both DLPFC
- pregnant women
- with severe physical diseases such as heart, lung, liver and kidney
- brain death
- new intracerebral lesions in patients during the study period affecting the assessment and prognosis, e.g. new stroke
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: tDCS treatment group
On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
|
On the basis of conventional treatment, tDCS was given on day 2 after enrollment for a total of 14 days, once a day.
|
|
Experimental: rTMS treatment group
On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
|
On the basis of conventional treatment, rTMS was given on day 2 after enrollment for a total of 14 days, once a day.
|
|
No Intervention: conventional treatment group
Not receiving any neuromodulation treatment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
CRS-R
Time Frame: day 15 of enrollment
|
The unabbreviated scale title is the coma recovery scale-revised.The CRS-R tests six components: auditory, language, visual, communication, motor and arousal levels, with a total score of 0-23.
The lower the score, the more severe the brain damage and the deeper the DOC level.
|
day 15 of enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
GCS
Time Frame: day 15 of enrollment
|
The unabbreviated scale title is Glasgow coma score.
The GCS tested 3 components: eye opening response, verbal response and motor response, with a total score of 15.
The lower the score, the more severe the brain damage and the deeper the degree of DOC.
|
day 15 of enrollment
|
|
FOUR
Time Frame: day 15 of enrollment
|
The unabbreviated scale title is full outline of unresponsiveness.
The FOUR tested 4 components: eye opening response, brainstem reflex, respiratory pattern and motor response, with a total score of 0-16.
The lower the score, the more severe the brain damage and the deeper the degree of DOC.
|
day 15 of enrollment
|
|
MMN
Time Frame: day 15 of enrollment
|
The unabbreviated scale title is mismatch negative, representing an important component of auditory event-related potentials.
We measure the occurrence, latency and wave amplitude of MMN.
|
day 15 of enrollment
|
|
MEP
Time Frame: day 15 of enrollment
|
The unabbreviated scale title is motor evoked potential, which can examine the overall synchronization and integrity of the motor nerve transmission and conduction pathways from the cortex to the muscle.
We measure the occurrence, latency and wave amplitude of MEP.
|
day 15 of enrollment
|
|
ABCD model of neural oscillation
Time Frame: day 15 of enrollment
|
The total frequency content of the EEG is represented by a power spectrum that indicates the neural oscillations at different frequencies within the EEG signal.
the ABCD model roughly classifies these changes in the EEG power spectrum into four types of ABCD, and this model is thought to reflect the severity of thalamo-cortical neural afferent block and is used to understand the different degrees of structural and functional afferent impairment present in patients with DOC.
The ABCD model can reflect neural oscillations from A to D corresponding to the level of consciousness from DOC to wakefulness.
|
day 15 of enrollment
|
|
brain network transfer entropy
Time Frame: day 15 of enrollment
|
Information flow between neural networks is the basis for understanding brain signal processing and function.
Using the method of transfer entropy to analyze the information flow between two two channels, the wavelet consistency algorithm was applied to reveal the linear and nonlinear correlations between regional local field potentials, and the real-time coupling relationship between two channels of neural signals in time-frequency space, including coupling strength and coupling direction.
Brain network connectivity can be determined, and comatose patients have significantly weaker connectivity than normal whole brain.
|
day 15 of enrollment
|
|
brain network phase synchronization
Time Frame: day 15 of enrollment
|
The synchronization relationship between two two channels was analyzed using the method of phase synchronization to form a whole-brain synchronization matrix, and the synchronization matrix was calculated to analyze the direction and strength of whole-brain network connectivity by analyzing data such as shortest path and agglomeration coefficient in the small-world network index.
Brain network connectivity can be determined, and comatose patients have significantly weaker connectivity than normal whole brain.
|
day 15 of enrollment
|
|
Prognostic scores (mRS)
Time Frame: 3 months, 6 months, 12 months after DOC
|
The unabbreviated scale title is modified Rankin Scale.
The mRS includes 0-6, and the higher the score, the worse the prognosis.
|
3 months, 6 months, 12 months after DOC
|
|
Prognostic scores (GOS)
Time Frame: 3 months, 6 months, 12 months after DOC
|
The unabbreviated scale title is Glasgow Outcome Scale.
GOS includes a score of 1-5, with the higher the score, the better the prognosis.
|
3 months, 6 months, 12 months after DOC
|
|
Prognostic scores (CRS-R)
Time Frame: 3 months, 6 months, 12 months after DOC
|
The unabbreviated scale title is the coma recovery scale-revised.
The CRS-R includes a total score of 0-23.The lower the score, the worse the prognosis.
|
3 months, 6 months, 12 months after DOC
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Signs and Symptoms, Respiratory
- Brain Ischemia
- Hypoxia
- Brain Diseases
- Consciousness Disorders
- Hypoxia, Brain
- Hypoxia-Ischemia, Brain
Other Study ID Numbers
Other Study ID Numbers
- DOC1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.